AnaptysBio, Inc. (LON:0HFQ)

AnaptysBio Statistics

Total Valuation

AnaptysBio has a market cap or net worth of GBP 928.58 million. The enterprise value is 1.00 billion.

Market Cap	928.58M
Enterprise Value	1.00B

Important Dates

The next estimated earnings date is Monday, March 2, 2026.

Earnings Date	Mar 2, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	27.69M
Shares Outstanding	n/a
Shares Change (YoY)	+7.36%
Shares Change (QoQ)	+0.72%
Owned by Insiders (%)	2.85%
Owned by Institutions (%)	70.66%
Float	14.40M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	7.37
PB Ratio	-42.43
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-15.90
EV / Sales	7.93
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-9.26

Financial Position

The company has a current ratio of 8.68

Current Ratio	8.68
Quick Ratio	8.52
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-2.38
Interest Coverage	-0.37

Financial Efficiency

Return on equity (ROE) is -308.02% and return on invested capital (ROIC) is -4.66%.

Return on Equity (ROE)	-308.02%
Return on Assets (ROA)	-4.23%
Return on Invested Capital (ROIC)	-4.66%
Return on Capital Employed (ROCE)	-9.10%
Revenue Per Employee	927,009
Profits Per Employee	-462,939
Employee Count	136
Asset Turnover	0.40
Inventory Turnover	n/a

Taxes

In the past 12 months, AnaptysBio has paid 57,283 in taxes.

Income Tax	57,283
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +183.77% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+183.77%
50-Day Moving Average	37.52
200-Day Moving Average	25.44
Relative Strength Index (RSI)	60.34
Average Volume (20 Days)	224

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	9.83

Income Statement

In the last 12 months, AnaptysBio had revenue of GBP 126.07 million and -62.96 million in losses. Loss per share was -2.14.

Revenue	126.07M
Gross Profit	12.25M
Operating Income	-21.33M
Pretax Income	-62.90M
Net Income	-62.96M
EBITDA	-20.91M
EBIT	-21.33M
Loss Per Share	-2.14

Balance Sheet

The company has 185.21 million in cash and 257.74 million in debt, giving a net cash position of -72.53 million.

Cash & Cash Equivalents	185.21M
Total Debt	257.74M
Net Cash	-72.53M
Net Cash Per Share	n/a
Equity (Book Value)	-21.88M
Book Value Per Share	-0.79
Working Capital	217.64M

Cash Flow

In the last 12 months, operating cash flow was -107.85 million and capital expenditures -259,635, giving a free cash flow of -108.11 million.

Operating Cash Flow	-107.85M
Capital Expenditures	-259,635
Free Cash Flow	-108.11M
FCF Per Share	n/a

Margins

Gross margin is 9.72%, with operating and profit margins of -16.92% and -49.94%.

Gross Margin	9.72%
Operating Margin	-16.92%
Pretax Margin	-49.89%
Profit Margin	-49.94%
EBITDA Margin	-16.58%
EBIT Margin	-16.92%
FCF Margin	n/a

Dividends & Yields

AnaptysBio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-7.36%
Shareholder Yield	-7.36%
Earnings Yield	-6.78%
FCF Yield	-11.64%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

AnaptysBio has an Altman Z-Score of -1.06 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.06
Piotroski F-Score	3